MeiraGTx Holdings plc
MGTX · XNASCIK 1735438fmd_12TSBJJ6XAYKD6FXCMBQKDQEX3Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 38 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 13 | 16 | 38 | 16 | 14 | 33 | 81 |
| Research and development | 22 | 34 | 25 | 34 | 67 | 86 | 104 | 119 | 130 |
| Selling, general and administrative | – | – | – | – | – | – | – | 78 | 58 |
| Total operating expenses | 32 | 78 | 72 | 78 | 110 | 132 | 151 | 197 | 187 |
| Operating income | (32) | (78) | (58) | (63) | (73) | (116) | (137) | (164) | (106) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 5 | 13 | 13 | 12 |
| Interest and investment income | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 4 | 2 |
| Income before taxes | (31) | (83) | (55) | (58) | (80) | (130) | (84) | (148) | (114) |
| Income tax expense | 0 | (0) | 0 | 0 | 0 | – | 0 | 0 | 0 |
| Net income from continuing operations | (31) | (83) | (55) | (58) | (80) | – | (84) | (148) | (114) |
| Net income | (31) | (83) | (55) | (58) | (80) | (130) | (84) | (148) | (114) |
| Net income to common shareholders | (32) | (85) | (55) | (58) | (80) | (130) | (84) | (148) | (114) |